Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RUTI Vaccine in MDR-TB Patients
NCT02711735Phase 2Terminated
- Sponsor
- Archivel Farma
- Start
- Mar 2020
- Primary completion
- Sep 2020
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multidrug-resistant tuberculosis (MDR-TB) comparing RUTI Vaccine with Placebo (2 arms). Primary endpoint: Clinical safety parameters related to vaccination at 8 weeks. Started Mar 2020; status: terminated.
02
Drugs
RUTI vaccine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT02711735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02711735.